Pulmonx
Mahtab brings over 20 years of experience in regulatory affairs, research and quality assurance to Pulmonx, including 12 years in interventional pulmonology. She has worked on a broad range of medical devices, drugs, combination products and diagnostics. Prior to joining Pulmonx, Mahtab was VP of Regulatory Affairs and Quality at Nuvaira, Inc., a company developing device-based treatments for COPD. Mahtab has also driven regulatory strategies for asthma and migraine products while at MAP Pharmaceuticals, and started her regulatory affairs career at BD Biosciences. Mahtab holds a BS in Biology from UC Irvine, a MS in Physiology from Georgetown University and a JD from Santa Clara University School of Law, and is a member of the California Bar.
This person is not in any offices
Pulmonx
2 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1